Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 402

Showing 26-50 of 402 citing articles:

A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Nature (2025)
Open Access | Times Cited: 1
No time for complacency on COVID-19 in Europe
Antoine Flahault, Alexandra Calmy, Dominique Costagliola, et al.
The Lancet (2023) Vol. 401, Iss. 10392, pp. 1909-1912
Open Access | Times Cited: 16
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 16
Comparison between the Viral Illness Caused by SARS-CoV-2, Influenza Virus, Respiratory Syncytial Virus and Other Respiratory Viruses in Pediatrics
Giulia Brigadoi, Giulia Camilla Demarin, Riccardo Boracchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 199-199
Open Access | Times Cited: 7
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects
Е. Л. Насонов
Rheumatology Science and Practice (2024) Vol. 62, Iss. 1, pp. 32-54
Open Access | Times Cited: 7
New perspective of small-molecule antiviral drugs development for RNA viruses
Shasha Li, Huixia Li, Ruiya Lian, et al.
Virology (2024) Vol. 594, pp. 110042-110042
Closed Access | Times Cited: 7
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 7
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 7
Modulation of alveolar macrophage and mitochondrial fitness by medicinal plant-derived nanovesicles to mitigate acute lung injury and viral pneumonia
Lusha Ye, Yanan Gao, Simon Wing Fai Mok, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)
Giulia Barchielli, Antonella Capperucci, Damiano Tanini
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 1-2, pp. 17-49
Open Access | Times Cited: 6
Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation
Nathan Gf Leborgne, Christelle Devisme, Nedim Kozarac, et al.
JCI Insight (2024) Vol. 9, Iss. 7
Open Access | Times Cited: 6
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 6
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
Karen Anbro Gammeltoft, Yuyong Zhou, Line A. Ryberg, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1970-1970
Open Access | Times Cited: 13
Evaluation of in vitro antiviral activity of SARS-CoV-2 M pro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
Xiao Tong, Walter Keung, Lee D. Arnold, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 11
Open Access | Times Cited: 13
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
Prakash D. Jadhav, Bo Huang, J. Osipiuk, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 116011-116011
Open Access | Times Cited: 13
A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
Yang Yang, Junfang Zhang, Shengnan Zhang, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 13
Myocardial Oedema as a Consequence of Viral Infection and Persistence—A Narrative Review with Focus on COVID-19 and Post COVID Sequelae
N Panagiotides, Michael Poledniczek, Martin Andreas, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 121-121
Open Access | Times Cited: 5
A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin
Luis Adrián De Jesús‐González, Rosa M. del Ángel, Selvin Noé Palacios-Rápalo, et al.
Microorganisms (2024) Vol. 12, Iss. 2, pp. 383-383
Open Access | Times Cited: 5
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109363-109363
Open Access | Times Cited: 5
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 5
Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein
Xiafei Wei, Yuzheng Zhou, Xiaotong Shen, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2505-2519
Open Access | Times Cited: 5
A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection
Yang Yu, Si Chen, Haonan Zhang, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Open Access | Times Cited: 5
A pyrazinamide-benzenesulfonohydrazide hybrid N'-(phenylsulfonyl)pyrazine-2-carbohydrazonamide: experimental and theoretical insights
Vali Alizadeh, Isabel García‐Santos, A. Castiñeiras, et al.
Tetrahedron (2024) Vol. 162, pp. 134066-134066
Closed Access | Times Cited: 5
PDZ2-conjugated-PLGA nanoparticles are tiny heroes in the battle against SARS-CoV-2
Noah Giacon, Ettore Lo Cascio, Valeria Pennacchietti, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5

Scroll to top